XLO: Bathi resik saben saham (EPS TTM) Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. (XLO) focuses on developing "smart" drugs for oncology clinics where insurance companies guarantee payment. The rolling annual earnings per share confirms the growth trend, with the value -0.41 representing the current metric. Diversification of the immunotherapeutic portfolio minimizes risks, while independence from macroeconomic factors makes the company's biotechnologies a stable defensive asset during recessionary periods.
Xilio - rincian analitis lan metrik utama (XLO)

Net income per share over 12 months measures the portion of total income attributable to a single common share. This metric neutralizes the impact of the total shares outstanding, allowing for an assessment of the business's actual efficiency. By analyzing the 12-month net income per share trend, an investor identifies the sustainability of the trend excluding one-time factors. For Xilio Therapeutics, Inc. (XLO), negative values reflect a stage of intensive capital expenditure. This confirms that investments in clinical trials are prioritized over current profitability.